While a number of studies have shown a correlation between the expression of CSC markers such as CD133, CD44, CD166 [88], Lgr5 [89] and Bmi1 [90] and survival, much less is known about the correlation of expression of these markers and the CSC phenotype in metastatic disease. This evidence concerns the gene PROM1 and metastatic neoplasm.